Table 3 Patient characteristics of physiological parameters at MRI examination

Current Plasma-Creatinine, µmol/l [IQR]

104 [101–114]

67 [64–77]

Current eGFR (Creatinine), ml/min [IQR]

56 [49–59]

87 [78–90]

Current KDIGO Creatinine AKI Stage

1 [1–1]

Last recorded hourly urine output, ml/kg [IQR]

0.9 [0.3–1.7]

1 [0.8–1.7]

Last recorded hourly urine output, ml [IQR]

65 [35–131]

110 [80–150]

Furosemide within 12 h before MRI scan, mg [IQR]

8 [1–10]

0 [0–0]

Time since latest furosemide, h [IQR]

7 [5–20]

28 [17–36]

Any furosemide within 3 h before MRI scan, n (%)

2 (20%)

1 (11%)

Net fluid intake at examination day, ml [IQR]

318 [− 15 to 629]

184 [-16–429]

SOFA score, points [IQR]

7 [7, 8]

6 [4–6]

Days of symptomatic COVID-19, n [IQR]

17 [14–19]

12 [11–14]

Days in ICU at examination, n [IQR]

8 [4–8]

3 [2–5]

Plasma-CRP, mg/l [IQR]

98 [71–140]

115 [64–186]

Days since start of invasive ventilation, n [IQR]

4 [2–5]

2 [2, 3]

Arterial oxygen saturation

96% [93–97]

95% [95–98]

Arterial pO₂, kPa [IQR]

10 [10, 11]

10 [10–12]

Arterial pCO₂, kPa [IQR]

6.3 [5.7–6.6]

5.5 [5.2–6]

Arterial pH, [IQR]

7.39 [7.37–7.41]

7.42 [7.4–7.44]

P/f-ratio, kPa [IQR]

21 [20–27]

26 [25–33]

PEEP, cmH₂O [IQR]

14 [13–15]

10 [9–12]

Mean arterial pressure, mmHg [IQR]

80 [79–85]

81 [80–98]

Sinus rhythm, n (%)

10 (100%)

8 (89%)

Blood hemoglobin, g/dl [IQR]

11.5 [11.3–12.3]

12.8 [11.4–12.9]

Central venous saturation, [IQR]

73% [72–77]

67% [65–74]

Vasoactive drug, n (%)

8 (80%)

4 (44%)

Noradrenaline dose, µg/kg/min [IQR]

0.05 [0.01–0.07]

0 [0–0.03]

Plasma-lactate, mmol/l [IQR]

1.4 [1–1.9]

1.5 [1.3–1.6]

Plasma-NT-proBNP, ng/l [IQR]

201 [131–633]

373 [236–491]